CURE Pharmaceutical (OTCMKTS:CURR) Stock Price Up 21.3%

Shares of CURE Pharmaceutical Holding Corp. (OTCMKTS:CURRGet Rating) rose 21.3% during trading on Tuesday . The company traded as high as $0.34 and last traded at $0.34. Approximately 57,296 shares traded hands during trading, an increase of 34% from the average daily volume of 42,846 shares. The stock had previously closed at $0.28.

CURE Pharmaceutical Stock Up 21.3 %

The stock has a 50 day moving average price of $0.17 and a 200 day moving average price of $0.23. The stock has a market capitalization of $26.28 million, a price-to-earnings ratio of -0.92 and a beta of 0.50.

CURE Pharmaceutical (OTCMKTS:CURRGet Rating) last announced its quarterly earnings results on Tuesday, November 22nd. The company reported ($0.04) EPS for the quarter. CURE Pharmaceutical had a negative net margin of 403.86% and a negative return on equity of 154.12%. The firm had revenue of $1.78 million for the quarter.

CURE Pharmaceutical Company Profile

(Get Rating)

CURE Pharmaceutical Holding Corp., a biopharmaceutical company, focuses on the development and manufacturing of drug formulation and drug delivery technologies to enhance drug safety, efficacy, and patient adherence. It operates through two segments, Cure and Sera Labs. The company's pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; CUREfilm Canna, a cannabinoid product with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data; and CUREfilm Central Nervous System, a novel dosage form to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety.

Recommended Stories

Receive News & Ratings for CURE Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CURE Pharmaceutical and related companies with's FREE daily email newsletter.